UCB : Showcases Commitment to Advancing Care in Immune-Media

adults with severe active AS who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs .


Axial spondyloarthritis without... | May 30, 2023

Related Keywords

Brussels , Bruxelles Capitale , Belgium , Milan , Lombardia , Italy , Sweden , Morup , Halland , United Kingdom , Great Britain , Eimear Obrien , J Clin Pharmacol , Laurent Schots , Antje Witte , Wenzel Kragstrup , Emmanuel Caeymaex , Dapirolizumab Pegol , Brand Communications , European Congress , Immunology Solutions , Twitter , Corporate Communications , European Union Eu Economic Area , Executive Vice President , Orbaia M , Psoriatic Arthritis Impact , Systemic Lupus , Psoriatic Arthritis , Rieem Dun , European Union , European Economic Area , Safety Information , Magnetic Resonance Imaging , Euronext Brussels , Product Characteristics , Study Participants With Moderately , Severely Active Systemic Lupus Erythematosus , Ucb Stock Exchange , News , Information , Press Release , Adults , Ith , Evere , Ctive , Us , Who , Wave , Sad , N , Inadequate , Response , Dr , Fire , Intolerant , O , Drugs , Coaxial , Pondyloarthritis Ucb Be0003739530 ,